Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$66.20 ▼ -0.08
(-0.12%)
MKT CAP: $16.40B • VOL: 2.84M
52W L $36 52W H $72
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$56
MEDIAN
$74
MEAN
$75
HIGH
$90
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE EXEL TAPE
EXEL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $80.10 | $76.13 | 2025-02-14 | $60.24 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $83.41 | $78.12 | 2025-02-06 | $62.23 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $75.47 | $72.82 | 2025-01-29 | $63.55 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $67.52 | — | 2025-01-17 | $64.88 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $58.26 | $62.89 | 2025-01-09 | $58.92 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $78.78 | $68.85 | 2024-12-18 | $57.59 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $64.21 | $66.86 | 2024-12-04 | $61.57 | -4.3% | 48% | C |